303 results on '"Lapa, Daniele"'
Search Results
2. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
3. Kinetics of viral DNA in body fluids and antibody response in patients with acute Monkeypox virus infection
4. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
5. Autochthonous Dengue Fever in 2 Patients, Rome, Italy
6. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
7. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
8. Rift Valley Fever Virus: An Overview of the Current Status of Diagnostics
9. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
10. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation
11. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV
12. Protocolos e Algoritmos para Manejo das Síndromes Perinatais e Pediátricas
13. Protocolos e Algoritmos para Manejo das Síndromes Perinatais
14. Protocolos e Algoritmos para Manejo das Síndromes Perinatais
15. Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries
16. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH
17. Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination
18. Detection of Anti-Rift Valley Fever Virus Antibodies in Serum Samples of Patients with Suspected Arbovirus Infection
19. Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis
20. Effect of chemical and physical agents on monkeypox virus infectivity and downstream research applications
21. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
22. Recovery from Triple Infection with SARS-CoV-2, RSV and Influenza virus: a case report
23. Diagnostics of Ebola virus
24. Alpha, Beta, gamma human PapillomaViruses (HPV) detection with a different sets of primers in oropharyngeal swabs, anal and cervical samples
25. Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
26. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
27. Viral replication and infectivity of monkeypox through semen – Authors' reply
28. External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021
29. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay
30. External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021
31. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
32. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance
33. Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.
34. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
35. In HIV/HCV Coinfected Patients Dendritic Cell Activation State Is Not Associated With IL28B Genotype
36. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
37. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
38. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
39. Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021
40. Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization
41. Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients
42. Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination
43. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
44. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
45. Live and Replication-Competent SARS-CoV-2 in Ocular Fluids
46. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
47. Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization
48. Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy
49. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
50. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.